Last Update 18 Feb 26

Fair value Increased 2.98%

SPRY: Competitor FDA Setback And Global Approvals Will Support Future Upside

Analysts now see fair value for ARS Pharmaceuticals rising slightly from about $28.00 to roughly $28.83 per share, citing the recent FDA deficiency letter to a key competitor as support for their updated price target and underlying assumptions.

Analyst Commentary

Bullish Takeaways

Bullish analysts view the FDA deficiency letter to a key competitor as easing near term competitive pressure on ARS Pharmaceuticals, which they see as supportive of the updated fair value near US$28.83 per share.
The potential delay to a rival product's market entry is seen as giving ARS Pharmaceuticals more time to execute on its own launch and commercial plans without direct pressure from an additional entrant.
Analysts point out that safety concerns previously raised by ARS Pharmaceuticals about the competing therapy appear aligned with the current regulatory scrutiny, which they see as reinforcing the risk profile advantage for ARS Pharmaceuticals' product.
The revised price target is described as reflecting analysts' confidence in management's ability to convert this competitive window into improved execution and cash flow visibility over time.

Bearish Takeaways

Bearish analysts caution that the FDA review for the competitor's product is still ongoing, so regulatory outcomes could change and reduce any perceived competitive advantage for ARS Pharmaceuticals.
Some see the updated fair value as embedding expectations that ARS Pharmaceuticals fully capitalizes on the potential delay to the rival product, leaving less room for execution missteps.
There is concern that investors may be focusing too heavily on competitor setbacks rather than on ARS Pharmaceuticals' own clinical, regulatory, and commercial milestones that still need to be delivered.
A prolonged review process for the competitor also highlights regulatory uncertainty in this treatment area overall, which cautious analysts see as a reminder that ARS Pharmaceuticals is exposed to similar review risks over time.

What’s in the News

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending expansion of the EURneffy marketing authorization to include a 1 mg nasal adrenaline spray for children weighing at least 15 kg and under 30 kg. This would extend the existing 2 mg approval for adults and heavier children across the EU, Iceland, Liechtenstein and Norway (Key Developments).
neffy is commercially available in the U.S. for emergency treatment of allergic reactions, including anaphylaxis, in adults and children who weigh at least 33 pounds. Recent regulatory approvals have also been reported in Japan, China and Australia through regional partners (Key Developments).
Canadian regulatory approvals for neffy are described as expected in early 2026. Partner ALK has launched EURneffy 2 mg in selected European countries and the U.K., indicating ongoing geographic rollout activity (Key Developments).
China’s National Medical Products Administration approved neffy 2 mg epinephrine nasal spray for adults and children who weigh 30 kg or more. ARS Pharmaceuticals and Pediatrix Therapeutics plan to file for a 1 mg pediatric dose in the coming months (Key Developments).
ARS Pharmaceuticals announced multiple upcoming data presentations on neffy at the 2026 American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting. These presentations will include health economic analyses, patient preference work, usability studies and pharmacokinetic comparisons versus injectable epinephrine products (Key Developments).

Valuation Changes

Fair Value: updated slightly higher from about $28.00 to roughly $28.83 per share.
Discount Rate: adjusted marginally from 7.32% to about 7.35%.
Revenue Growth: kept effectively unchanged at around 45.34%.
Net Profit Margin: maintained at roughly 10.29% with only a minimal numerical adjustment.
Future P/E: increased modestly from about 77.48x to roughly 79.06x.

3 views

Key Takeaways

Accelerating demand and expanded access for neffy, especially in pediatric and school settings, is driving significant revenue and earnings growth opportunities.
Global expansion, new clinical indications, and strong market penetration strategies are broadening revenue streams and creating multiple long-term growth drivers.
Dependence on a single product, high marketing spend, pricing pressures, and rising competition create substantial risks to sustainable growth and profitability.

Catalysts

About ARS Pharmaceuticals

A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.What are the underlying business or industry changes driving this perspective?

Increasing global prevalence of severe allergies and anaphylaxis, alongside rising awareness of rapid allergic reaction treatment, is expanding the long-term demand for needle-free emergency therapies like neffy-which is reflected in accelerating prescription growth and should drive sustained top-line revenue expansion.
Growing pediatric and school-based adoption-supported by program engagement, recent pediatric dosing approvals, and legislative updates in multiple states-positions neffy to capture untapped patient pools, increasing revenue scale and supporting durable earnings growth as the addressable market broadens.
Successful global rollout initiatives, with neffy launches in Germany and the UK and pending regulatory approvals in Canada, Australia, Japan, and China, create a catalyst for international revenue growth and milestone payments, diversifying and expanding overall revenue streams.
Rapid removal of access barriers (93% payer coverage, reduced prior authorization requirements, high co-pay support adoption) combined with a robust DTC campaign is improving market penetration, which is likely to drive further revenue growth and enhance net margins via operating leverage as sales increase.
Expansion of intranasal epinephrine indications (e.g., ongoing Phase IIb clinical trial in chronic spontaneous urticaria) could unlock high-value new use cases for neffy, creating future growth drivers for both top-line revenue and long-term earnings.

ARS Pharmaceuticals Earnings and Revenue Growth

ARS Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming ARS Pharmaceuticals's revenue will grow by 54.7% annually over the next 3 years.
Analysts assume that profit margins will increase from -42.7% today to 17.7% in 3 years time.
Analysts expect earnings to reach $73.7 million (and earnings per share of $0.68) by about September 2028, up from $-48.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $82.5 million in earnings, and the most bearish expecting $-53.5 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 52.8x on those 2028 earnings, up from -22.4x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 1.69% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

ARS Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Heavy reliance on neffy as a single lead asset exposes ARS to significant product concentration risk; any future regulatory setbacks, commercial issues, or competitive pressures directly threaten topline revenue and earnings due to lack of diversification.
Intense investment in DTC marketing and high SG&A expenses, without assurance of sustained DTC effectiveness or ultimate script conversion, could pressure near
and mid-term net margins and increase risk of poor operating leverage if prescription growth plateaus.
Industry-wide drug price transparency, reimbursement pressures, and increased gross-to-net (GTN) deductions are already compressing ARS's net product revenue; ongoing payer negotiations and co-pay support could further erode long-term profitability.
Advancing competition in non-injectable epinephrine or alternative anaphylaxis treatments, or disruptive next-generation delivery methods from larger or more resourceful pharma, could quickly diminish neffy's commercial opportunity, affecting future revenue growth.
Global expansion is dependent on partnership milestones, successful international regulatory approvals, and country-specific market adoption, all of which encounter substantial execution risk and could delay or cap multi-year revenue and earnings scalability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $31.0 for ARS Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $25.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $415.9 million, earnings will come to $73.7 million, and it would be trading on a PE ratio of 52.8x, assuming you use a discount rate of 6.8%.
Given the current share price of $10.88, the analyst price target of $31.0 is 64.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ARS Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Worldwide Allergy Trends Will Expand Needle-Free Treatment Access